EGFL7 Inhibits the Immune Response in Metastatic Castration-Resistant Prostate Cancer by Deactivating Endothelial...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Epidermal growth factor-like 7 (EGFL7) is implicated in various cancers.
• The specific role of EGFL7 in prostate cancer (PCa) progression, especially in metastatic castration-resistant prostate cancer (mCRPC), is not well understood.
• Understanding EGFL7's function in PCa is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the biological function of EGFL7 in prostate cancer.
• To determine the association between EGFL7 and immune regulation in PCa.
• To explore EGFL7 as a potential therapeutic target in advanced PCa.

Main Methods:

• Quantified EGFL7 and intercellular adhesion molecule-1 (ICAM-1) in serum and prostate tissues from patients with benign prostatic hyperplasia (BPH), localized PCa, and mCRPC.
• Manipulated EGFL7 expression (silencing or overexpression) in PCa cell lines (DU145, PC3).
• Conducted xenograft experiments in nude mice and analyzed tumor tissues via microarray.

Main Results:

• EGFL7 expression was significantly higher in mCRPC serum and tissues compared to BPH and localized PCa.
• EGFL7 knockdown suppressed PCa cell proliferation, migration, and invasion, while increasing ICAM-1 and immune cell infiltration in vivo.
• EGFL7 overexpression promoted tumor progression and decreased ICAM-1 levels.

Conclusions:

• EGFL7 overexpression in mCRPC downregulates endothelial ICAM-1, suppressing immune cell infiltration.
• EGFL7 plays a critical role in prostate cancer progression and immune evasion.
• EGFL7 represents a promising therapeutic target for advanced prostate cancer.